Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial.
COVID-19
Corticosteroids
Randomized clinical trial
Remdesivir
Tenofovir
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
17 Oct 2024
17 Oct 2024
Historique:
received:
08
06
2024
accepted:
12
08
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
The global effort to cure COVID-19 is still ongoing. Thus, a prospective, block-balanced, open-label, randomized controlled trial was conducted to evaluate how Tenofovir Alafenamide Fumarate affects hospitalized COVID-19 patients' outcomes. The intervention and control groups of 60 hospitalized COVID-19 patients were randomly allocated. Along with normal medication, the intervention group received 25 mg of tenofovir orally daily for seven days. The control group got normal therapy, including remdesivir and corticosteroids. ICU hospitalization duration, laboratory data, fever, dyspnea, arterial blood oxygen saturation with and without an oxygen face mask, mechanical ventilation, and mortality were the outcomes. Sixty of 236 eligible patients between September 2020 and February 2021 were enrolled. The intervention group had a mean age (±SD) of 61.33 (±13.09) years and the control group 60.03 (±18.03). Sixteen (53.3%) intervention patients and 15 (50.0%) control patients were males. The intervention group had fewer mechanical ventilation and ICU days. Tenofovir Alafenamide Fumarate did not improve fever, dyspnea, oxygen saturation with or without a face mask or nasal cannula, or laboratory data including WBC, ESR, CRP, AST, ALT, AlkP, total and direct bilirubin, in COVID-19 patients. According to this pilot trial, Tenofovir Alafenamide Fumarate, along with conventional treatment, significantly reduced mechanical ventilation and ICU stay in COVID-19 patients. Further thorough research is necessary to verify this conclusion.
Sections du résumé
BACKGROUND
BACKGROUND
The global effort to cure COVID-19 is still ongoing. Thus, a prospective, block-balanced, open-label, randomized controlled trial was conducted to evaluate how Tenofovir Alafenamide Fumarate affects hospitalized COVID-19 patients' outcomes.
METHODS
METHODS
The intervention and control groups of 60 hospitalized COVID-19 patients were randomly allocated. Along with normal medication, the intervention group received 25 mg of tenofovir orally daily for seven days. The control group got normal therapy, including remdesivir and corticosteroids. ICU hospitalization duration, laboratory data, fever, dyspnea, arterial blood oxygen saturation with and without an oxygen face mask, mechanical ventilation, and mortality were the outcomes.
RESULTS
RESULTS
Sixty of 236 eligible patients between September 2020 and February 2021 were enrolled. The intervention group had a mean age (±SD) of 61.33 (±13.09) years and the control group 60.03 (±18.03). Sixteen (53.3%) intervention patients and 15 (50.0%) control patients were males. The intervention group had fewer mechanical ventilation and ICU days. Tenofovir Alafenamide Fumarate did not improve fever, dyspnea, oxygen saturation with or without a face mask or nasal cannula, or laboratory data including WBC, ESR, CRP, AST, ALT, AlkP, total and direct bilirubin, in COVID-19 patients.
CONCLUSION
CONCLUSIONS
According to this pilot trial, Tenofovir Alafenamide Fumarate, along with conventional treatment, significantly reduced mechanical ventilation and ICU stay in COVID-19 patients. Further thorough research is necessary to verify this conclusion.
Identifiants
pubmed: 39420385
doi: 10.1186/s40360-024-00781-3
pii: 10.1186/s40360-024-00781-3
doi:
Substances chimiques
Tenofovir
99YXE507IL
tenofovir alafenamide
EL9943AG5J
Alanine
OF5P57N2ZX
Antiviral Agents
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
78Informations de copyright
© 2024. The Author(s).
Références
Davis JS, Ferreira D, Denholm JT, Tong SY. Clinical trials for the prevention and treatment of COVID-19: current state of play. Med J Aust. 2020;213(2):86–93.
doi: 10.5694/mja2.50673
pmcid: 7361919
pubmed: 32594562
Rommasi F, Nasiri MJ, Mirsaiedi M. Antiviral drugs proposed for COVID-19: action mechanism and pharmacological data. Eur Rev Med Pharmacol Sci. 2021;25(11):4163–73.
pubmed: 34156698
Pramesh CS, Babu GR, Basu J, Bhushan I, Booth CM, Chinnaswamy G, et al. Choosing wisely for COVID-19: ten evidence-based recommendations for patients and physicians. Nat Med. 2021;27(8):1324–7.
doi: 10.1038/s41591-021-01439-x
pubmed: 34226738
García-Albéniz X, Del Amo J, Polo R, Morales-Asencio JM, Hernán MA. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. Eur J Epidemiol. 2022;37(8):789–96.
doi: 10.1007/s10654-022-00891-4
pmcid: 9360718
pubmed: 35943669
Naggie S, Milstone A, Castro M, Collins SP, Lakshmi S, Anderson DJ, et al. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker exposure response and outcomes of Hydroxychloroquine (HERO-HCQ). Int J Infect Dis. 2023;129:40–8.
doi: 10.1016/j.ijid.2023.01.019
pmcid: 9851717
pubmed: 36682681
Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2020;173(7):536–41.
doi: 10.7326/M20-3689
pubmed: 32589451
Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Antiretrovirals and risk of COVID-19 diagnosis and hospitalization in HIV-positive persons. Epidemiology. 2020;31(6):e49–51.
doi: 10.1097/EDE.0000000000001235
pmcid: 7541717
pubmed: 32773469
Copertino Jr DC, Casado Lima BC, Duarte RR, Powell TR, Ormsby CE, Wilkin T, et al. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. J Biomol Struct Dyn. 2022;40(16):7367–80.
doi: 10.1080/07391102.2021.1901144
pubmed: 33734021
Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. Tenofovir, another inexpensive, well-known and widely available old drug repurposed for SARS-COV-2 infection. Pharmaceuticals. 2021;14(5):454.
doi: 10.3390/ph14050454
pmcid: 8150375
pubmed: 34064831
Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, et al. Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state. AIDS Res Hum Retroviruses. 2016;32(10–11):981–91.
doi: 10.1089/aid.2016.0008
pmcid: 5067852
pubmed: 27526873
Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):re1124–4.
doi: 10.1126/scitranslmed.3003174
De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016;119:1–7.
doi: 10.1016/j.bcp.2016.04.015
pubmed: 27133890
Drosu NC, Edelman ER, Housman DE. Tenofovir prodrugs potently inhibit Epstein–Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc Natl Acad Sci. 2020;117(22):12368–74.
doi: 10.1073/pnas.2002392117
pmcid: 7275665
pubmed: 32409608
Clososki GC, Soldi RA, Silva RMd, Guaratini T, Lopes JN, Pereira PR, et al. Tenofovir disoproxil fumarate: new chemical developments and encouraging in vitro biological results for SARS-CoV-2. J Braz Chem Soc. 2020;31:1552–6.
Birkus G, Bam RA, Willkom M, Frey CR, Tsai L, Stray KM, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother. 2016;60(1):316–22.
doi: 10.1128/AAC.01834-15
pubmed: 26503655
Huang M, Wang Y, Ye J, Da H, Fang S, Chen L. Dynamic changes of T-lymphocyte subsets and the correlations with 89 patients with coronavirus disease 2019 (COVID-19). Ann Transl Med. 2020;8(18).
Mitjà O, Corbacho-Monné M, Ubals M, Tebé C, Peñafiel J, Tobias A, et al. Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial. Clin Infect Dis. 2021;73(11):e4073–81.
doi: 10.1093/cid/ciaa1009
pubmed: 32674126
Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Inter Med. 2020;173(8):623–31.
doi: 10.7326/M20-4207
Lorizate M, Kräusslich H-G. Role of lipids in virus replication. Cold Spring Harb Perspect Biol. 2011;3(10):a004820.
doi: 10.1101/cshperspect.a004820
pmcid: 3179339
pubmed: 21628428
Melchjorsen J, Risør MW, Søgaard OS, O’Loughlin KL, Chow S, Paludan SR, et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr. 2011;57(4):265–75.
doi: 10.1097/QAI.0b013e3182185276
pubmed: 21471820
Zı́dek Zk, Franková D, Holý A. Activation by 9
doi: 10.1128/AAC.45.12.3381-3386.2001
Eisenberg EJ, He G-X, Lee WA. Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood. Nucleosides Nucleotides Nucleic Acids. 2001;20(4–7):1091–8.
doi: 10.1081/NCN-100002496
pubmed: 11562963
Markowitz M, Zolopa A, Ruane P, Squires K, Zhong L, Kearney B, et al. editors. GS-7340 demonstrates greater declines in HIV-1 RNA than tenofovir disoproxil fumarate during 14 days of monotherapy in HIV-1 infected subjects. 18th Conference on Retroviruses and Opportunistic Infections; 2011.
Guan WJ, Zhong NS. Clinical characteristics of Covid-19 in China. Reply. N Engl J Med. 2020;382(19):1861–2.
pubmed: 32220206
Peluso L, Abella BS, Ferrer R, Kucher N, Sunde K, Taccone FS. Fever management in COVID-19 patients. Minerva Anestesiol. 2021;87(1):1–3.
doi: 10.23736/S0375-9393.20.15195-2
pubmed: 33231411
Shokati Eshkiki Z, Shahriari A, Seyedtabib M, Torabizadeh M, Assarehzadegan MA, Nashibi R, Khosravi M, Neisi N, Mard SA, Shayesteh AA. Innate and adaptive immunity imbalance with severe COVID-19 pneumonia in children and adults. Front Pediatr. 2021;9:736013.
doi: 10.3389/fped.2021.736013
pmcid: 8714948
pubmed: 34976886
Levitan RM. Pulse oximetry as a biomarker for early identification and hospitalization of COVID-19 pneumonia. Acad Emerg Med. 2020;27(8):785.
doi: 10.1111/acem.14052
pmcid: 7323007
pubmed: 32779867
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet]. 2022.
Kow CS, Ramachandram DS, Hasan SS. The use of tenofovir in patients with COVID-19. HIV Med. 2022;23(7):807–8.
doi: 10.1111/hiv.13228
pubmed: 35023263
Mateos-Muñoz B, Buti M, Vázquez IF, Conde MH, Bernal-Monterde V, Díaz-Fontenla F, et al. Tenofovir disoproxil fumarate reduces the severity of COVID-19 in patients with chronic hepatitis B. Dig Dis Sci. 2023:1–7.
Polo R, García-Albéniz X, Terán C, Morales M, Rial-Crestelo D, Garcinuño MA, et al. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers. Clin Microbiol Infect. 2023;29(1):85–93.
doi: 10.1016/j.cmi.2022.07.006
pubmed: 35940567
Painter WP, Sheahan T, Baric R, Holman W, Donovan J, Fang L, et al. Reduction in infectious SARS-CoV-2 in treatment study of COVID-19 with molnupiravir. Top Antivir Med. 2021:304–5.
DeJong C, Spinelli MA, Okochi H, Gandhi M. Tenofovir-based PrEP for COVID-19: an untapped opportunity? AIDS. 2021;35(9):1509.
doi: 10.1097/QAD.0000000000002877
pubmed: 33710026
Hernandez-Diaz S, Bateman BT, Straub L, Zhu Y, Mogun H, Fischer M, et al. Safety of tenofovir disoproxil fumarate for pregnant women facing the coronavirus disease 2019 pandemic. Am J Epidemiol. 2021;190(11):2339–49.
doi: 10.1093/aje/kwab109
pubmed: 33847737